Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression (Q35979241)

11 August 2017

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression (English)

1 reference

11 August 2017

1 reference

3

Lønning PE

1 reference

11 August 2017

MacNeill FA

1

1 reference

11 August 2017

Jacobs S

series ordinal

2

1 reference

11 August 2017

Powles TJ

series ordinal

4

1 reference

11 August 2017

Dowsett M

series ordinal

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 June 1994

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

69

1 reference

11 August 2017

6

1 reference

11 August 2017

1171-1175

1 reference

Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Additive effects of aminoglutethimide, testololactone, and 4-hydroxyandrostenedione as inhibitors of aromatase

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Inhibition of aromatase with CGS 16949A in postmenopausal women

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1969459

Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma

24 September 2018

1 reference

12 December 2020

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

12 December 2020

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

1 reference

12 December 2020

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

1 reference

12 December 2020

The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings

1 reference

12 December 2020

1 reference

12 December 2020

A phase I trial of CGS 16949A. A new aromatase inhibitor

1 reference

12 December 2020

Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione

1 reference

12 December 2020

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide

1 reference

12 December 2020

The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects

1 reference

12 December 2020

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients

1 reference

12 December 2020

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.230

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

PubMed publication ID

8198987

1 reference